NCT00924053View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

EGT0001474

Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.

DRUG

Placebo

Placebo capsules to match EGT0001474

Trial Locations (1)

78229

dgd Research Inc., a Cetero Research Company, San Antonio

Sponsors

Lead Sponsor

Theracos
All Listed Sponsors
lead

Theracos

INDUSTRY

NCT00924053 - Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter